Marché mondial des médicaments contre la trichomonase – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché des médicaments contre la trichomonase

Aux États-Unis, le nombre de cas de trichomonase était d'environ 2 570 002 en 2017. De plus, les cas de trichomonase spécifiques au sexe étaient plus nombreux chez les femmes et s'élevaient à 2 073 893 dans le pays. Aux États-Unis, environ 70 % des cas de trichomonase sont asymptomatiques. L'augmentation des cas de rapports sexuels non protégés a entraîné une propagation accrue de la maladie.

Data Bridge Market Research analyse le taux de croissance du marché des médicaments contre la trichomonase au cours de la période de prévision 2023-2030. Le TCAC attendu du marché des médicaments contre la trichomonase a tendance à être d'environ 4,50 % au cours de la période de prévision mentionnée. Le marché était évalué à 63,2 milliards USD en 2022 et atteindrait 90 milliards USD d'ici 2030. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée et segmentation du marché des médicaments contre la trichomonase

Définition du marché

Trichomoniasis is a sexually transmitted disease (STD) which is caused by the flagellated protozoan parasite that is transmitted from one person to another during intercourse. The parasite usually transmits from a vagina to a penis or from penis to a vagina, and many times, from a vagina to another vagina. Men and women are both suffering from trichomoniasis globally and the commonly infected part of the body in women is the lower genital tract such as cervix, vagina, vulva, or urethra, while that in men is the inside of the penis.

Trichomoniasis Drugs Market Dynamics

Drivers

• Increase in Trichomoniasis

Rise in the occurrence rate of Trichomoniasis disease is one of the primary factors for the growth of the market. In 2020, WHO witnessed 374 million new cases of STIs globally out of which 176 million new cases of trichomoniasis are found all over the world and the increasing in public awareness about STDs. Rise in R&D activities associated with discovering an effective therapy for the condition are the major drivers for the growth of the market.

• Increased Drug Approvals

The increasing number of drug launches and approvals lead to the growth of the market. For instance, on 28 January 2022, Glenmark Pharmaceuticals Inc., US received final approval from the FDA for Metronidazole Vaginal Gel, 0.75%, the generic version of MetroGel-Vaginal1 Gel, 0.75%, of Bausch Health US, LLC. Furthermore, on 6 September 2021, Aleor Dermaceuticals received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Metronidazole Gel USP, 1%. Thus, this boosts the market growth.

Opportunities

• Growing Acquisitions by Different Market Players

The increasing number of acquisitions that are led by numerous market players lead to the growth of the market. For instance, on 29 March 2022, Alembic Pharmaceuticals Ltd fully acquired Aleor Dermaceuticals Limited. Aleor Dermaceuticals provides products in many of formulations, which includes creams, micro sponge, gels, shampoos, lotions, ointments, solutions, sprays, foams, and platform-based nanoparticle products and this acquisition will further increase capability of Alembic pharma in manufacturing and marketing products of various skin related diseases

Restraints/Challenges

• Increased Awareness About Sexually Transmitted Diseases

Increase in awareness about the spread of sexually transmitted diseases such as HIV and rising need of evading them by using preventive measures such as use of condoms can diminish the incidence of STD leading to delaying revenue growth of the market.

This trichomoniasis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the trichomoniasis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Trichomoniasis Drugs Market Scope

The trichomoniasis drugs market is segmented on the basis of drug type, product type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Metronidazole
• Tinidazole

Product Type

• Tablet
• Suppository/Pessaries
• Cream
• IV

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Trichomoniasis Drugs Market Regional Analysis/Insights

The trichomoniasis drugs market is analyzed and market size insights and trends are provided by drug type, product type, distribution channel and end-user as referenced above.

The major countries covered in the trichomoniasis drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market due to rise in the better health care infrastructure, rise in the economic growth, rise in the growth of the private health care sector and increase in awareness among people in this region.

Asia-Pacific dominates the market due to increase in the number of insurance payers and rise in the growth of the private health care sector in these regions.  

La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché mondiales des médicaments contre la trichomonase

Le paysage concurrentiel du marché des médicaments contre la trichomonase fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des médicaments contre la trichomonase.

Les principaux acteurs opérant sur le marché des médicaments contre la trichomonase comprennent :

• Pfizer Inc. (États-Unis)
• Lupin (Inde)
• Teva Pharmaceuticals Industries Ltd. (Israël)
• Groupe Zydus (Inde)
• Les Compagnies de Santé Bausch Inc. (Canada)
• Missionpharma A/S (Danemark)
• Zauba Technologies & Data Services Private Limited (Inde)
• Mission Pharmacal Company (États-Unis)
• Unique Pharmaceuticals Limited.(Afrique)
• Edenbridge Pharmaceuticals, LLC (États-Unis)

SKU-61497